Medincell SA
PAR:MEDCL
Medincell SA
Research & Development
Medincell SA
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Medincell SA
PAR:MEDCL
|
Research & Development
-€24.9m
|
CAGR 3-Years
-1%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
N/A
|
|
|
Sanofi SA
PAR:SAN
|
Research & Development
-€7.8B
|
CAGR 3-Years
-5%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
-4%
|
|
|
Ipsen SA
PAR:IPN
|
Research & Development
-€754m
|
CAGR 3-Years
-19%
|
CAGR 5-Years
-13%
|
CAGR 10-Years
-15%
|
|
|
Vetoquinol SA
PAR:VETO
|
Research & Development
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Virbac SA
PAR:VIRP
|
Research & Development
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Boiron SA
PAR:BOI
|
Research & Development
-€5.7m
|
CAGR 3-Years
-9%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
-3%
|
|
Medincell SA
Glance View
MedinCell SA is a pharmaceutical company, which engages in the development of injectable products in therapeutic areas. The company is headquartered in Jacou, Occitanie and currently employs 150 full-time employees. The company went IPO on 2018-10-08. The firm is focused on the development of therapeutic solutions with worldwide access. The firm works on both for-profit and non-profit projects, in collaboration with partners ranging from pharmaceutical corporations to physicians, from biotechnology firms to academics and foundations. Its range of products consists of three products in development phase: mdc-IRM, a subcutaneous injection in phase III clinical study for the treatment of schizophrenia; mdc-CWM, an intra-articular injection in phase II clinical study for the treatment of post-surgical pain and inflammation; mdc-TJK, a subcutaneous injection for the treatment of schizophrenia, as well as a number of other products that are in the research phase, such as mdc-WWM, which is a subcutaneous injection for contraception, and mdc-ELK, a subcutaneous injection for the treatment of depression, among others.
See Also
What is Medincell SA's Research & Development?
Research & Development
-24.9m
EUR
Based on the financial report for Sep 30, 2025, Medincell SA's Research & Development amounts to -24.9m EUR.
What is Medincell SA's Research & Development growth rate?
Research & Development CAGR 5Y
-11%
Over the last year, the Research & Development growth was -38%. The average annual Research & Development growth rates for Medincell SA have been -1% over the past three years , -11% over the past five years .
